Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0026764 (multiple myeloma)
 36,148 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Pyoderma gangrenosum (PG) is an uncommon ulcerative disease of the skin. The cause is unknown but the condition is often associated with other diseases such as rheumatoid arthritis, ulcerative colitis, Crohn's disease or monoclonal gammopathy. The association between PG and haematological malignancies (acute leukaemia, Myeloproliferative disorders) is infrequent. Two cases of PG associated with haemopathy are described; one had primary thrombocythaemia and the other, acute myeloblastic leukaemia following for myeloma. The significance of this association is discussed in the light of other observations previously reported in the literature.
 ...
PMID:[Pyoderma gangrenosum and hemopathies. Apropos of 2 cases]. 348 May 4

An identical chromosome abnormality, which appears to be derived from a 1;7 translocation [+der(1),t(1;7)(p11;p11)], was observed in the bone marrow of 12 patients with various hematologic disorders at the Mayo Clinic from 1980 to 1984. At the time of cytogenetic evaluation, nine of the patients had either a myeloproliferative disorder or a myelodysplastic syndrome, one had an acute leukemia, and two had treated multiple myeloma with no morphologic evidence of evolving myeloproliferative disease. Of the 11 patients for whom information about previous therapy was available, seven had a history of exposure to chemotherapy for a previous malignant disorder; we were unable to establish whether the remaining patient had had prior treatment. This study suggests a possible relationship between +der(1),t(1;7)(p11;p11) and some treatment-induced hematologic disorders. Such chromosome abnormalities may be the result of a reciprocal chromatid translocation and adjacent I segregation of a quadriradial configuration in metaphase.
 ...
PMID:Unbalanced 1;7 translocation and therapy-induced hematologic disorders: a possible relationship. 370 88

Sixty-seven patients with hematological malignancies and 4 with cancers were evaluated in this study. Standard administration of MCNU was instituted intravenously using 50-100 mg/m2 every 2 or 4 weeks, whereas some cases were treated with a higher dose therapy. Of 10 patients with chronic myelogenous leukemia, 7 achieved complete remission (CR), and 1 achieved partial remission (PR). A good response was also obtained in 9 of 10 patients with polycythemia vera and in all 4 patients with essential thrombocythemia. MCNU was less effective in malignant lymphoma (ML) and multiple myeloma (MM) than in myeloproliferative disorders. Two of 15 patients with ML and one of 21 patients with MM achieved CR, and two with ML and three MM achieved PR. Three patients with lung cancer and 1 with gastric cancer showed no response to MCNU. Delayed anemia, leukocytopenia and thrombocytopenia were observed in 38.7% of patients, and these were regarded as major side effects of MCNU. Nausea, vomiting, anorexia and elevated transaminase were also found in about 24% of patients, but only transiently. Our study indicates that MCNU is useful for chemotherapy of hematological malignancies, especially of myeloproliferative disorders. Therefore, further studies on combination chemotherapy with MCNU should be developed.
 ...
PMID:[Phase II study of methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside (MCNU)]. 385 48

Five patients with myeloproliferative disorders and paraprotein are reported. The diseases included acute myelomonocytic leukemia, chronic myeloid leukemia, sideroblastic anemia with excess of blasts, polycythemia vera and myelofibrosis. In four cases, the paraprotein was of the IgG k type and in one, IgM k. No evidence of multiple myeloma or excessive plasmacytosis was noted. The literature records 19 other myeloid disorders with this unusual association. Although the pathogenesis remains unclear, three possible explanations are suggested: disturbance of the pluripotent stem cell resulting in a combined myeloplasmatic disorder, coexistence of two diseases, or a fortuitous association.
 ...
PMID:Myeloproliferative disorders and nonmyelomatous paraprotein. A study of five patients and review of the literature. 394 87

Five new cases of plasma cell dyscrasia with coexistent myelofibrosis are described and six previously reported cases are reviewed. Four of the new patients and two from the literature had features of a previously unrecognized syndrome. This syndrome was characterized by significant paraprotein levels, marked marrow fibrosis, and plasmacytosis, without features of extramedullary hematopoiesis (agnogenic myeloid metaplasia) and leukoerythroblastosis. These patients were generally severely anemic and commonly leukopenic and thrombocytopenic. In contrast, one of the new patients and four in the literature showed classic features of the myeloproliferative disease, myelofibrosis with agnogenic myeloid metaplasia, along with features of typical multiple myeloma.
 ...
PMID:Plasma cell dyscrasia with marrow fibrosis. Clinicopathologic syndrome. 403 81

Osteolytic defects and osteoporosis are common in myeloma, while sclerotic lesions of bone are rare. Eighteen patients with increased bone density have been described in the literature and five patients are presented in this report. Diffuse increase in skeletal density, similar to that seen in the myelofibrosis-myelosclerosis syndrome, occurred in two patients, and progressive multiple focal areas of sclerosis with splenomegaly in a third. Two patients had solitary areas of sclerosis. Although there was increased cortical and trabecular bone, osteoblastic activity was normal on histological sections. Whether the sclerosis was due to new bone formation or interference with bone resorptive processes could not be determined. Patients with polycythemia, myelofibrosis and myelosclerosis have been found to have, or later develop, myeloma. This has led to the suggestion that myeloma be included among the myeloproliferative disorders. At present the evidence for this interrelationship is the frequency of the association of these diseases.
 ...
PMID:Sclerotic lesions of bone in myeloma. 495 77

Serum beta 2 microglobulin (beta 2 mu) level was determined in 157 patients followed up for 1 to 38 months. In 42 patients with nonremissional lymphoproliferative malignancies, the observed values (mean 4.35 +/- 2.24 mg/l) were much higher than the beta 2 mu levels obtained either in the 37 healthy subjects (mean 1.86 +/- 0.30 mg/l) or in the 39 patients with various nonmalignant diseases (mean 2.68 +/- 1.76 mg/l). However, for diagnostic purposes serum beta 2 mu level determination is still of very limited value: if the beta 2 mu level is below 2.50 mg/l, the beginning of a hematologic malignancy cannot be excluded; beta 2 mu levels between 2.50 and 5.00 mg/l are observed, in most cases, with lymphoproliferative or myeloproliferative disorders, but these values are also often found in various diseases, particularly of viral or autoimmunological etiology; a serum beta 2 mu level above 5.00 mg/l was obtained only in lymphoproliferative malignancies and in one case of "acquired immuno deficiency syndrome" (AIDS) in a homosexual male. Serum beta 2 mu determination is of chief advantage in follow-up of Hodgkin's disease, of non-Hodgkin malignant lymphoma, of chronic lymphocytic leukemia and of multiple myeloma either during treatment or in remission.
 ...
PMID:[Beta 2 microglobulin]. 619 96

The serum levels of beta 2-microglobulin (beta 2m), which is the light chain moiety of the HLA (-A, -B, -C) antigens, are increased in many of the haematological malignancies. In the lymphoproliferative disorders there is generally an association between serum beta 2m and estimates of tumour load. This relationship is especially close in myelomatosis, where serum beta 2m is a powerful prognostic indicator and can be used in stratification and monitoring. Increases in serum beta 2m are also frequent in the myeloproliferative disorders, notably in myelofibrosis, and in the myelodysplastic syndromes; particularly high levels are seen in chronic myelomonocytic leukaemia. In addition to suggested cellular sources of the beta 2m in these diseases--malignant lymphoid cells and cells of the monocyte-macrophage series--the possibility that T lymphocyte sub-sets could be important contributors to the increased beta 2m production is discussed.
 ...
PMID:Serum beta 2-microglobulin in lymphoproliferative and myeloproliferative diseases. 639 93

The 4th case of plasma cell neoplasm associated with a hypereosinophilic syndrome is described and compared with the previous reports. Hypereosinophilia in the present patient displayed some borderline traits with eosinophilic leukemia. Myeloproliferative disorders of the eosinophilic line often present as a precancerous state, but sometimes they seem to acquire malignant independence. In our patient the occurrence of a plasmocytoma with a dramatic course leads to suspect an underlying complex genetic aberration.
 ...
PMID:Hypereosinophilic syndrome and plasmocytoma. Report of a case and review of the literature. 643 26

Four cases of polycythemia associated with myeloma are described. Three of four had polycythemia vera with IgA monoclonal gammopathy. The possible relationship between chronic myeloproliferative disorder and myeloma is discussed. Review of the literature revealed 11 such cases, four of which had a history of 32P therapy for polycythemia vera.
 ...
PMID:Polycythemia associated with myeloma. 647 48


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>